Guri A.A.O.

Guri A.A.O. is a South Korean biotechnology company dedicated to developing innovative small molecule therapeutics for inflammatory and immunological disorders, with a primary focus on dermatology. The company's lead candidate, GRA-011, is a novel topical agent currently being evaluated in clinical trials for the treatment of atopic dermatitis and psoriasis. Guri A.A.O. leverages its expertise in medicinal chemistry to design targeted inhibitors that modulate key signaling pathways in the immune system, such as Spleen tyrosine kinase. Headquartered in Guri, South Korea, the firm aims to address unmet medical needs in chronic skin conditions through its proprietary drug discovery pipeline. Their research efforts are specifically focused on providing safer alternatives to topical corticosteroids and existing systemic treatments.